-
Roth Capital Reiterates Buy on Madrigal Pharma (MDGL) Following 4Q and Clinical Confusion
-
Madrigal Pharmaceuticals (MDGL) PT Raised to $210 at Roth Capital Following MGL-3196 Achieving Primary Endpoint
-
Madrigal Pharma (MDGL) Prices 1.5M Share Common Offering at $83/Sh
-
Madrigal Pharmaceuticals Prices Public Offering of Common Stock
-
Madrigal Pharmaceuticals Prices Public Offering of Common Stock
-
Madrigal Pharmaceuticals (MDGL) PT Raised to $82 at Roth Capital Following Review of Primary Results From NASH Trial
-
Madrigal Pharmaceuticals (MDGL) PT Raised to $82 at Roth Capital
-
Roth Capital Starts Madrigal Pharmaceuticals (MDGL) at Buy

